Table 1.
A. Cdc42 and Rac1 variants used in the study. B. Inhibitors used in the study.
| A. Cdc42 and Rac1 variants used in the study | ||
| Small GTPase | Mutant | Phenotype |
| Cdc42 | Q61L | GTPase defective |
| G12V | GTPase defective | |
| T17N | Dominant negative (nucleotide binding-defective) | |
| F28L | Fast-cycling (increased GDP/GTP exchange) | |
| D118N | Elevated GDP/GTP exchange | |
| R66A | RhoGDI binding-defective | |
| T35A | Effector loop mutant | |
| F37A | Effector loop mutant | |
| Y40C | Effector loop mutant | |
| Δins | Insert domain mutant | |
| SAAX | CAAX box mutant | |
| Rac1 | Q61L | GTPase defective |
| T17N | Dominant negative (nucleotide binding- defective) | |
| F28L | Fast-cycling (increased GDP/GTP exchange) | |
| P29S | Fast-cycling (increased GDP/GTP exchange). Cancer mutation | |
| Rac1B | Fast-cycling (increased GDP/GTP exchange). Cancer mutation | |
| B. Inhibitors used in the study | ||
| Inhibitor | Concentration Used | Targeted Pathway |
| GGTI298 | 10 μM | Inhibitor of geranylgeranylation |
| FFT277 | 10 μM | Inhibitor of farnesylation |
| 2-bromopalmitate (2-BP) | 100 μM | Inhibitor of palmitoylation |
| SU6656 | 2 μM | Inhibitor of Src family kinases |
| LY294002 | 10 μM | Inhibitor of PI3 kinases |
| Y27632 | 10 μM | Inhibitor of Rho kinase (ROCK) |
| NSC23766 | 30 μM | Inhibitor of Rac |
| ML-141 | 10 μM | Inhibitor of Cdc42 |
| SMIFH2 | 30 μM | Inhibitor of formins |
| CK-666 | 100 μM | Inhibitor of Arp2/3 |